AngioDynamics, Inc. (NASDAQ:ANGO) Position Reduced by Shell Asset Management Co.

Shell Asset Management Co. decreased its position in shares of AngioDynamics, Inc. (NASDAQ:ANGOGet Rating) by 12.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,578 shares of the medical instruments supplier’s stock after selling 3,787 shares during the period. Shell Asset Management Co. owned 0.07% of AngioDynamics worth $551,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ANGO. Pinebridge Investments L.P. bought a new stake in AngioDynamics during the fourth quarter worth approximately $55,000. DekaBank Deutsche Girozentrale bought a new stake in AngioDynamics during the fourth quarter worth approximately $100,000. Teacher Retirement System of Texas bought a new stake in AngioDynamics during the fourth quarter worth approximately $204,000. Cornerstone Investment Partners LLC bought a new stake in AngioDynamics during the fourth quarter worth approximately $229,000. Finally, Lazard Asset Management LLC bought a new stake in AngioDynamics during the fourth quarter worth approximately $247,000. Institutional investors own 93.91% of the company’s stock.

AngioDynamics Price Performance

NASDAQ ANGO opened at $23.26 on Wednesday. The stock has a market capitalization of $906.44 million, a P/E ratio of -34.21 and a beta of 0.90. AngioDynamics, Inc. has a 1 year low of $17.56 and a 1 year high of $32.00. The business’s fifty day moving average is $20.22 and its two-hundred day moving average is $21.31. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.24 and a current ratio of 1.93.

AngioDynamics (NASDAQ:ANGOGet Rating) last posted its quarterly earnings data on Tuesday, July 12th. The medical instruments supplier reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. AngioDynamics had a negative net margin of 8.40% and a negative return on equity of 0.04%. The firm had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $82.91 million. AngioDynamics’s revenue was up 13.3% on a year-over-year basis. On average, research analysts forecast that AngioDynamics, Inc. will post 0.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AngioDynamics news, SVP Dave Helsel sold 5,000 shares of AngioDynamics stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $22.44, for a total transaction of $112,200.00. Following the transaction, the senior vice president now directly owns 23,822 shares in the company, valued at approximately $534,565.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ANGO. Raymond James dropped their target price on AngioDynamics from $32.00 to $27.00 and set a “strong-buy” rating on the stock in a report on Wednesday, July 13th. TheStreet cut AngioDynamics from a “c-” rating to a “d+” rating in a report on Friday, July 8th. Finally, Canaccord Genuity Group dropped their price target on AngioDynamics from $40.00 to $35.00 in a report on Wednesday, July 13th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

AngioDynamics Profile

(Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Recommended Stories

Want to see what other hedge funds are holding ANGO? Visit to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGOGet Rating).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.